-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsBinod DhakalMedical College of Wisconsin, Milwaukee, WIBinod Dhakal, Shruti Sharma, Svetlana Shchegrova, Minu Maninder, Meenakshi Malhotra, Himanshu Sethi, Bernhard Zimmermann, Paul R. Billings, Alexey Aleshin, Parameswaran HariOrganizationsMedical College of Wisconsin, Milwaukee, WI, Natera, Inc., San Carlos, CA, Omicia, Oakland, CAAbstract DisclosuresResearch FundingNo funding…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
DetailsCitationJ Clin Oncol 39, 2021 (suppl 15; abstr 9105)AuthorsEyob ale TadesseAurora Cancer Care, Advocate Aurora Health, Milwaukee, WIEyob ale Tadesse, Kayla Heslin, Mohamed Hendawi, Luke Peterson, Frank M. Wolf, Thomas D. Brown, Michael A. ThompsonOrganizationsAurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, Advocate Aurora Health, Milwaukee, WI, Syapse INC, San Francisco, CA,…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsMohamed HendawiAurora Cancer Care, Advocate Aurora Health, Milwaukee, WIMohamed Hendawi, Luke Peterson, Eyob ale Tadesse, Frank M. Wolf, Thomas D. Brown, Michael A. ThompsonOrganizationsAurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, Syapse INC, San Francisco, CA, Syapse, San Francisco, CAAbstract DisclosuresResearch FundingNo funding receivedNone Background: Patients (pts)…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Should We Teach Cost-Effectiveness of Cancer-Related Therapies in Oncology Training? - 2 year(s) ago
With the current pace of progress in cancer care, urgent implementation of cost-effectiveness training curriculum in fellowship training programs will be indispensable, shares Dr. Samer Al Hadidi.
Source: ASCO ConnectionCategories: Hem/Oncs, Latest HeadlinesTweet-
We tried last year to present a cost effectiveness 101 educational talk #ASCO21 . Unfortunately this didn’t work out. We (@inas_md @amarkelkar & myself) are 1 year older & will try again maybe next year😁 @ASCO #ASCO23 ?! Check why IMO this is important 👇 https://t.co/2nQdZVl1p2 https://t.co/y1nyimVDLx
-
-
Mashup Score: 5Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies - 2 year(s) ago
This cross-sectional study evaluates the representation of racial and ethnic minority groups in breast, prostate, lung, and colorectal cancer studies with a focus on precision medicine objectives.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC... by Niels WJC van de Donk - 2 year(s) ago
EHA Library; WJC van de Donk N. Jun 9 2021; 324601;
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet
Personalized, ctDNA analysis to detect minimal residual disease & identify Pts at high risk of relapse w/ multiple myeloma - @bhemato et al. @Phari #ASCO21 Abstract 8029 https://t.co/OyywlExqea #mmsm #mmMRD n=28 BM flow vs @NateraOncology Signatera MRD @ 3 months post-AHCT https://t.co/fu9J0c659X